Description

APRETUDE (Cabotegravir) Injection delivers cabotegravir as a long?acting injectable suspension at 200?mg/ml concentration. A 3?ml IM dose provides 600?mg, administered every two months following two initiation injections. Cabotegravir is an integrase strand transfer inhibitor with exceptionally long elimination half?life (5.6–11.5 weeks). In research use, it simulates long?acting HIV prophylaxis (PrEP), enables pharmacokinetics modeling of depot release, and supports the study of integrase inhibitor activity. Each kit contains one vial. Intended strictly for laboratory research purposes.

Product Specifications

Mechanism of Action & Research Applications

Cabotegravir inhibits HIV integrase, blocking viral DNA integration into host genome. Its extended-release formulation enables steady systemic exposure for many weeks. APRETUDE Injection is used in research to model long?acting PrEP, study depot pharmacokinetics, monitor integrase inhibitor activity, and design sustained-release antiviral protocols. With administration every two months, it enables simulation of real-world long?acting prophylaxis models. FDA Access Data

Side Effects (For Reference Only in Research Models)

Research analogs may include injection-site reactions (pain, swelling), headache, mild fever, fatigue, and rare transient systemic effects. These observations offer guidance for safety and dosing in experimental studies.

Disclaimer

APRETUDE (Cabotegravir) Injection is strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic application.